Obsidian Therapeutics, Inc.OBX
Oncology7 cited findings · profile updated 2026-08-20
20.00 USDnot live — refreshed daily
About Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. (OBX) is an oncology research site. The company's drug candidate, OBX-115, is currently in a Phase 2 trial. OBX-115 has received both Fast Track and Regenerative Medicine Advanced Therapy designations in the United States.
In the Phase 2 trial, OBX-115 demonstrated a confirmed objective response rate (ORR) of 67%. Among the 15 patients evaluated, there were 2 Complete Responses and multiple Partial Responses.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| confirmed objective response rate (ORR) | 67% | Obsidian Therapeutics, Inc. — SEC 8-K (2026-08-14), p.1 |
| Complete Responses | 2 | Obsidian Therapeutics, Inc. — SEC 8-K (2026-08-14), p.1 |
| Partial Responses | multiple | Obsidian Therapeutics, Inc. — SEC 8-K (2026-08-14), p.2 |
| Designation | Fast Track | Obsidian Therapeutics, Inc. — SEC 8-K (2026-08-14), p.2 |
| Designation | Regenerative Medicine Advanced Therapy | Obsidian Therapeutics, Inc. — SEC 8-K (2026-08-14), p.2 |
Key projects
- OBX-115
OBX-115 is in a Phase 2 trial.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Oncology research library →